[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-356133-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-356133-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","screening-of-cytochrome-cyp26a1-expression-in-different-bone-tumors","Screening of cytochrome CYP26A1 expression in different bone tumors","","Cytochrome P450 26A1 (CYP26A1) is a retinoic-acid–metabolizing enzyme that is frequently overexpressed in cancers, yet its pattern in bone tumors remained insufficiently described. Using immunohistochemistry on 95 cases across benign, intermediate, and malignant bone tumors with accompanying normal bone, CYP26A1 staining was absent in normal tissue. It appeared in 31.6% of tumors, with intermediate lesions showing markedly higher frequency. Functional enrichment supported CYP26A1’s involvement in retinoid metabolic pathways.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/screening-of-cytochrome-cyp26a1-expression-in-different-bone-tumors/356133/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/screening-of-cytochrome-cyp26a1-expression-in-different-bone-tumors/356133.png","ImageObject",300,407,{"name":42,"@type":43},"mieayamfan","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is CYP26A1, and why was it studied in bone tumors?","Question",{"text":63,"@type":64},"CYP26A1 is a retinoic acid–metabolizing enzyme implicated in regulating retinoid signaling. The study assessed how CYP26A1 is expressed across different bone tumor types, since this had not been characterized.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was CYP26A1 expression measured in the study?",{"text":68,"@type":64},"CYP26A1 expression was evaluated using immunohistochemistry on a spectrum of bone diseases including benign, intermediate, and malignant tumors, together with normal bone samples.",{"name":70,"@type":61,"acceptedAnswer":71},"Which bone tumor category showed the highest CYP26A1 expression?",{"text":72,"@type":64},"Intermediate bone tumors expressed CYP26A1 significantly more often than benign and malignant tumors. Within intermediate tumors, giant cell tumors showed the highest detection frequency with weak staining intensity.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},356133,1790168092,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},962090893677,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Al-zu’bi etal. BMC Cancer (2026) 26:1027 BMC Cancer  \n[https://doi.org/10.1186/s12885-026-16366-8](https://doi.org/10.1186/s12885-026-16366-8)  \nRESEARCH Open Access  \nScreening of cytochrome CYP26A1 expression in different bone tumors  \nBelal Al-zu’bi1*, Fatemah O. F. O. Alshammari2, Randa AlQaisi3, Ahmed. A. Al-abadleh 1,4, Anas O. Satari5, Sameeh Al-Sarayreh6, Yousef M. Al-saraireh7* and Mohammad Salem Hareedy7  \nAbstract  \nBackground Cytochrome P450 26A1 (CYP26A1) is a retinoic acid metabolizing enzyme which is overexpressed in many cancers. However, its expression in bone tumors has not been characterized.  \nMethods Immunohistochemistry was used to evaluate CYP26A1 expression in a human bone disease spectrum comprising duplicated cores of 95 cases of benign, intermediate and malignant bone tumors alongside normal bone samples. STRING database was utilized to perform CYP26A1 protein–protein interaction and functional enrichment analyses.  \nResults CYP26A1 staining was not identified in the normal bone samples analyzed. Collectively, CYP26A1 was expressed in 31 . 6%(30/95) of bone tumors, with cytoplasmic localization, while no immunoreactivity was detected in normal tissues. Compared with benign (18 . 8%) and malignant tumors (27 . 1%), intermediate bone tumors expressed CYP26A1 significantly more frequently (66 . 7%) . This difference in expression between tumor categories was statistically confirmed (p \u003C 0. 05, Cramér’s V = 0 . 382) . Among intermediate tumors, CYP26A1 was detected with high frequency and weak staining intensity in giant cell tumors (GCTs, 14/20 cases), with immunoreactivity localized mainly in osteoblast-like and osteocyte-like stromal cells. Malignant bone tumors predominantly showed focal or an absence of CYP26A1 immunoreactivity. However, strong CYP26A1 immunoreactivity was displayed in the limited chordoma and adamantinoma cases examined, while osteosarcoma and Ewing sarcoma displayed no immunoreactivity in general. Interestingly, functional enrichment analysis confirmed the established association of CYP26A1 with retinoid metabolic pathways.  \nConclusions CYP26A1 expression was most frequent in giant cell tumors of bone. While also detected in a subset of other bone tumors, expression was limited or absent in most benign and malignant lesions, and entirely absent in normal bone tissue. These findings provide novel descriptive insight into CYP26A1 distribution and support further investigation into its role in retinoid-related pathways in bone tumor biology.  \nKeywords CYP26A1, Bone tumors, Immunohistochemistry, Benign and malignant bone lesions  \n*Correspondence:  \nBelal Al-zu’bi  \nbelal88@MUTAH.EDU.JOYousef M. Al-saraireh [Yousef.sar@mutah.edu.jo](Yousef.sar@mutah.edu.jo)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nAl-zu’bi et al. BMC Cancer (","cbCaihnqjnZ3YcPe","https://ap.wps.com/l/cbCaihnqjnZ3YcPe","pdf",2184076,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What is CYP26A1, and why was it studied in bone tumors?\",\"answer\":\"CYP26A1 is a retinoic acid–metabolizing enzyme implicated in regulating retinoid signaling. The study assessed how CYP26A1 is expressed across different bone tumor types, since this had not been characterized.\"},{\"question\":\"How was CYP26A1 expression measured in the study?\",\"answer\":\"CYP26A1 expression was evaluated using immunohistochemistry on a spectrum of bone diseases including benign, intermediate, and malignant tumors, together with normal bone samples.\"},{\"question\":\"Which bone tumor category showed the highest CYP26A1 expression?\",\"answer\":\"Intermediate bone tumors expressed CYP26A1 significantly more often than benign and malignant tumors. Within intermediate tumors, giant cell tumors showed the highest detection frequency with weak staining intensity.\"}]","Screening of cytochrome CYP26A1 expression in different bone tumors | PDF",1790123562,23,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0d27af2fbd7c0b945203589c91d29efa.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/271733efe18b71450bc6935e8822b104.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d5e90f6ad5b13a5fb3c18c452f96b244.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a366054b4ce7a27d4af5604ad963ca4b.webp",980,1306]